A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patient must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is metastatic or unresectable. 2. Patients must have either progressed after receiving prior therapy for metastatic disease, or be ineligible for, or have refused all other currently available therapeutic options.

You may not be eligible for this study if the following are true:

  • 1. Patient has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active infection, or psychiatric illness/social situation that would limit compliance with study requirements. 2. Patient has had prior chemotherapy, targeted cancer therapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks of starting study. 3. Patients with untreated brain metastases.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.